ICON PLC

DUBLIN --(BUSINESS WIRE)--Aug. 20, 2026-- ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading clinical research organisation, today releases its ICON Cares 2025 Report which outlines how the company is delivering on its environmental, social and governance (ESG) priorities with cutting-edge clinical

DUBLIN --(BUSINESS WIRE)--Aug. 6, 2026-- ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading clinical research organization, today announced the pricing by its wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the “Issuer”) of $2.15 billion of senior unsecured notes,

DUBLIN --(BUSINESS WIRE)--Aug. 4, 2026-- ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading clinical research organization, announced today that its wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the “Issuer”), intends to offer one or more series of senior notes (the

DUBLIN --(BUSINESS WIRE)--Jul. 31, 2026-- ICON plc   (NASDAQ: ICLR), a world-leading clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 31, 2026 were duly passed by shareholders.

Highlights Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. Quarter two adjusted EBITDA of $327.2 million or 15.9% of revenue, an increase of 3.0% on quarter one 2026. GAAP net income for the quarter of $72.6 million or $0.94 diluted earnings per share.

DUBLIN --(BUSINESS WIRE)--Jul. 28, 2026-- ICON plc (NASDAQ: ICLR) today announced a multi-year collaboration with Anthropic to bring Claude’s AI capabilities across the clinical trial lifecycle. The collaboration further advances ICON’s digital innovation and AI strategy, and builds on Orbis –

DUBLIN --(BUSINESS WIRE)--Jul. 22, 2026-- ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization, today announced that it will release its financial results for the second quarter 2026 after the market closes on Wednesday, July 29, 2026.

Highlights Quarter one revenue of $2,034.0 million, an increase of 0.9% on quarter one 2025. Quarter one adjusted EBITDA of $317.7 million or 15.6% of revenue. GAAP net income for the quarter of $104.8 million or $1.36 diluted earnings per share. Quarter one   adjusted net income   of $192.9

DUBLIN --(BUSINESS WIRE)--Jun. 22, 2026-- ICON plc (NASDAQ: ICLR) today announced that it has selected Microsoft as a preferred technology partner – further advancing ICON’s previously announced plan to invest in digital innovation and AI over the next three years.

DUBLIN --(BUSINESS WIRE)--Jun. 17, 2026-- ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization, today announced that it will release its financial results for the first quarter 2026 after the market closes on Tuesday, June 23, 2026.